Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia

Bayrak, Muharrem; DAL, Derya

Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia

Muharrem BAYRAK, (Sağlık Bilimleri Üniversitesi, Erzurum Bölge Eğitim ve Araştırma Hastanesi İç Hastalıkları Kliniği, Erzurum, Türkiye)

Derya DAL (Sağlık Bilimleri Üniversitesi, Erzurum Bölge Eğitim ve Araştırma Hastanesi İç Hastalıkları Kliniği, Erzurum, Türkiye)

Kafkas Tıp Bilimleri Dergisi

5 0

Yıl: 2020 Cilt: 10 Sayı: 1 Sayfa Aralığı: 47 - 50 Metin Dili: İngilizce İndeks Tarihi: 26-05-2021

Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia

Öz:

Aim: Iron deficiency anemia (IDA) is one of the most important health problems in both fertile women and children living in devel-oping countries. This condition must be treated quickly and safely. The present study aimed to compare the efficacies of intravenous ferrous carboxymaltose treatment and oral iron treatment in repro-ductive-aged women with IDA.Material and Method: This retrospective study included 202 reproductive-aged women who were diagnosed as IDA with a he-moglobin level of <11 g/dL. Patients were divided into two groups to be administered a single dose of 1000 mg intravenous ferric carboxymaltose (n=112) and 325 mg/day oral ferrous sulphate (n=90) for four weeks. All the anemia parameters of the patients were compared before and after treatment.Results: There were significant increases in hemoglobin con-centration, ferritin values, and transferrin saturation levels after treatment in both groups. However, the increases in these val-ues were significantly higher in the group receiving ferric car-boxymaltose (p<0.001). There was no significant difference in the side effects between the group receiving ferric carboxymaltose and the group receiving oral ferrous sulphate (6.7% vs. 8.9%, p=0.554).Conclusion: Ferric carboxymaltose treatment could be used ef-fectively and reliably in patients who could not tolerate oral iron treatmen

Anahtar Kelime:

Demir Eksikliği Anemisinde Ferrik Karboksimaltoz ile Oral Demir Tedavisinin Karşılaştırılması

Öz:

Amaç:Demir eksikliği anemisi (DEA), hem doğurgan kadınlar-da ve hem de gelişmekte olan ülkelerde yaşayan çocuklarda en önemli sağlık sorunlarından biridir. Bu durumun hızlı ve güvenli bir şekilde tedavi edilmesi önemlidir. Bu çalışma, demir eksikliği anemisi olan üreme çağındaki kadınlarda intravenöz ferrik karbok-simaltoz tedavisi ve oral demir tedavisinin etkilerini karşılaştırmayı amaçlamıştır. ateryal ve Metot:Bu retrospektif çalışmaya, DEA tanısı olan ve hemoglobin düzeyi <11 g/dL olan 202 reprodüktif dönemde kadın hasta alındı. Hastalar, dört hafta boyunca tek bir doz 1000 mg intra-venöz ferrik karboksimaltoz (n=112) ve 325 mg/gün oral demir sülfat (n=90) uygulanacak şekilde iki gruba ayrıldı. Hastaların tüm anemi pa-rametreleri tedavi öncesi ve sonrası karşılaştırıldı.Bulgular:Her iki grupta tedaviden sonra hemoglobin konsant-rasyonunda, ferritin değerlerinde ve transferrin doygunluk sevi-yelerinde önemli artışlar vardı. Bununla birlikte, bu değerlerde-ki artışlar ferrik karboksimaltoz alan grupta anlamlı olarak daha yüksekti (p<0,001). Ferrik karboksimaltoz alan grup ile oral demir sülfat alan grup arasında yan etkiler açısından anlamlı fark yoktu (%6,7’ye karşı %8,9, p=0,554).Sonuç:Ferrik karboksimaltoz tedavisi, oral demir tedavisini tolere edemeyen hastalarda etkili ve güvenilir bir şekilde kullanılabilir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1.. Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord 2011;11:4.
2. Rognoni C, Venturini S, Meregaglia M, Marmifero M, Tarricone R. Efficacy and safety of ferric carboxymaltose and other formulations in iron-deficient patients: a systematic review and network meta-analysis of randomised controlled trials. Clin Drug Investig 2016;36:177–94.
3. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva, Switzerland, 2011. http=//www.who.int/vmnis/indicators/haemoglobin.pdf [Accessed: 28/02/2019].
4. Shander A, Goodnough LT, Javidroozi M, Aurbach M, Carson J, Ershler WB, et al. Iron deficiency anemia-bridging the knowledge and practice gap. Transfus Med Rev 2014;28:156–66.
5. Auerbach M, Deloughery T. Single-dose intravenous iron for iron deficiency: a new paradigm. Hematolog y Am Soc Hematol Educ Program 2016;2016:57–66.
6. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PloS One 2015;10: e0117383.
7. Keating GM. Ferric carboxymaltose: a review of its use in iron deficiency. Drugs 2015;75:101–127.
8. Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med 2012;40(5):469–74.
9. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008;199(4):435. e1–7.
10. Barut A, Harma M. Intravenous iron treatment for iron deficiency anaemia in pregnancy. J Turk Ger Gynecol Assoc 2009;10:109–115.
11. Rohrig G, Steinmetz T, Stein J, Geisel T, Virgin G, Schaefer R, et al. Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studies. MMW Fortschr Med 2014 Jul 24;156 Suppl 2:48–53.
12. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 2013 Aug 15;347: f4822.
13. Gürbüz DÇ, Ulaş T, Paksoy F, Akgün ÖK, Tursun İ, Çakır A, et al. The effect of intravenous iron therapy on total antioxidant capacity in patients with iron deficiency anemia. J Clin Exp Invest 2011;2:287–91.
14. Altinbaş M, Imamoğlu I, Albayrak M, Ersoy U, Hacibekiroğlu I, Çolak D. Evaluation of intravenous iron therapy efficiency in patients with iron defıcıency anemia Ortadogu Medical Journal 2015, 7(2):79–82.
15. Breymann C, Milman N, Mezzacasa A, Bernard R, Dudenhausen J. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med 2017;45(4):443–453.
16. Smyth B, Ong S. Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interaction. Intern Med J 2016;46(3):360–3.
17. Blazevic A, Hunze J, Boots JM. Severe hypophosphataemia after intravenous iron administration. Neth J Med 2014;72(1):49–53

APA	Bayrak M, DAL D (2020). Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia. , 47 - 50.
Chicago	Bayrak Muharrem,DAL Derya Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia. (2020): 47 - 50.
MLA	Bayrak Muharrem,DAL Derya Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia. , 2020, ss.47 - 50.
AMA	Bayrak M,DAL D Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia. . 2020; 47 - 50.
Vancouver	Bayrak M,DAL D Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia. . 2020; 47 - 50.
IEEE	Bayrak M,DAL D "Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia." , ss.47 - 50, 2020.
ISNAD	Bayrak, Muharrem - DAL, Derya. "Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia". (2020), 47-50.

APA	Bayrak M, DAL D (2020). Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia. Kafkas Tıp Bilimleri Dergisi, 10(1), 47 - 50.
Chicago	Bayrak Muharrem,DAL Derya Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia. Kafkas Tıp Bilimleri Dergisi 10, no.1 (2020): 47 - 50.
MLA	Bayrak Muharrem,DAL Derya Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia. Kafkas Tıp Bilimleri Dergisi, vol.10, no.1, 2020, ss.47 - 50.
AMA	Bayrak M,DAL D Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia. Kafkas Tıp Bilimleri Dergisi. 2020; 10(1): 47 - 50.
Vancouver	Bayrak M,DAL D Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia. Kafkas Tıp Bilimleri Dergisi. 2020; 10(1): 47 - 50.
IEEE	Bayrak M,DAL D "Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia." Kafkas Tıp Bilimleri Dergisi, 10, ss.47 - 50, 2020.
ISNAD	Bayrak, Muharrem - DAL, Derya. "Comparison of Ferric Carboxymaltose andOral Iron Treatments in Iron Deficiency Anemia". Kafkas Tıp Bilimleri Dergisi 10/1 (2020), 47-50.